The largest database of trusted experimental protocols

Acc antibody 3662

Manufactured by Cell Signaling Technology

The ACC antibody (#3662) from Cell Signaling Technology is a primary antibody that recognizes acetyl-CoA carboxylase (ACC), an enzyme involved in fatty acid synthesis and metabolism. This antibody can be used for applications such as western blotting and immunohistochemistry.

Automatically generated - may contain errors

3 protocols using acc antibody 3662

1

Investigating mTOR and GSK3 Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
All mTOR kinase inhibitors, the GSK3 inhibitor SB216763, the proteasome inhibitor MG132, the protein synthesis inhibitor cycloheximide (CHX) and the antibodies against GSK3α/β, phospho-GSK3α/β (Ser21/9), phospho-Akt (Ser473), Akt, rictor and raptor were the same as described previously 22 (link). The GSK3 inhibitor CHIR99021 was purchased from LC laboratories (Woburn, MA). BKM120 was supplied by Novartis Pharmaceuticals Corporation (East Hanover, NJ). API-1 (NSC177233) was obtained from the National Cancer Institute (Bethesda, MD). MK2206 was purchased from Active Biochem (Maplewood, NJ). Perifosine was supplied by Keryx Biopharmaceuticals, Inc (New York, NY). Oil Red O was purchased from Sigma Chemical Co. (St. Louis, MO). SREBP1 (sc-13551), FASN (sc-55580) and α-tubulin (sc-23948) antibodies were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). ACC antibody (#3662) was purchased from Cell Signaling Technology, Inc. (Beverly, MA). Polyclonal Sin1 antibody (A300-910A) was purchased from Bethyl Laboratories, Inc. (Montgomery, TX).
+ Open protocol
+ Expand
2

Investigating mTOR and GSK3 Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
All mTOR kinase inhibitors, the GSK3 inhibitor SB216763, the proteasome inhibitor MG132, the protein synthesis inhibitor cycloheximide (CHX) and the antibodies against GSK3α/β, phospho-GSK3α/β (Ser21/9), phospho-Akt (Ser473), Akt, rictor and raptor were the same as described previously 22 (link). The GSK3 inhibitor CHIR99021 was purchased from LC laboratories (Woburn, MA). BKM120 was supplied by Novartis Pharmaceuticals Corporation (East Hanover, NJ). API-1 (NSC177233) was obtained from the National Cancer Institute (Bethesda, MD). MK2206 was purchased from Active Biochem (Maplewood, NJ). Perifosine was supplied by Keryx Biopharmaceuticals, Inc (New York, NY). Oil Red O was purchased from Sigma Chemical Co. (St. Louis, MO). SREBP1 (sc-13551), FASN (sc-55580) and α-tubulin (sc-23948) antibodies were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). ACC antibody (#3662) was purchased from Cell Signaling Technology, Inc. (Beverly, MA). Polyclonal Sin1 antibody (A300-910A) was purchased from Bethyl Laboratories, Inc. (Montgomery, TX).
+ Open protocol
+ Expand
3

Tissue-Specific Protein Expression Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Whole-cell lysates of liver, IWAT, and BAT were prepared by homogenizing tissue in buffer (150 mM sodium chloride, 1 mM EDTA, 1 mM EGTA, 10 mM Tris, 1% Triton X-100, 0.5% NP-40), and protein was quantitated by Lowry assay. Fifty microgram of whole-cell extracts was used for liver SCD1, 35 μg for liver FAS, 30 μg for liver ACC and IWAT UCP1, and 3 μg for BAT UCP1. Proteins were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. Expression of liver SCD1, FAS, ACC, and IWAT UCP1 were detected and standardized to β-actin (Sigma Millipore, St. Louis, MO; A-5441). The FASN (sc-48357) and SCD-1 (sc-14720; E-15) antibodies were from Santa Cruz Biotechnology (Dallas, TX), whereas the ACC antibody (#3662) was from Cell Signaling (Danvers, MA). PDC-E2 (sc-271534) was used as loading control for BAT UCP1 as described previously (Wanders et al., 2015 (link)).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!